Heart Failure Drugs Market Size, Share & Industry Analysis, By Drug Class (SGLT2 Inhibitors, ARNI, Beta Blockers, ACE Inhibitors & ARBs, Mineralocorticoid Receptor Antagonists, Diuretics, and Others), By Indication (HFrEF, HFpEF, HFmrEF, Acute Decompensated Heart Failure, Post-MI Heart Failure / LV Dysfunction, and Others), By Type (Branded and Generics), By Route of Administration (Oral and Parenteral), By Age Group (Adults and Pediatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: July 27, 2026 | Format: PDF | Report ID: FBI118447

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Challenges
5. Market Trends
Key Insights
1. Prevalence of Key Diseases, By Key Countries/Region
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
3. New Product Launches, By Key Players
4. Pipeline Analysis, By Key Players
5. Regulatory & Reimbursement Scenario, By Key Countries/Region
Global Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Novartis AG
  2. AstraZeneca
  3. Boehringer Ingelheim International GmbH
  4. Merck & Co., Inc.
  5. Amgen Inc.
  6. Pfizer Inc.
  7. LEXICON PHARMACEUTICALS, INC.
  8. Viatris Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. Sandoz Inc.

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Challenges
5. Market Trends
Key Insights
1. Prevalence of Key Diseases, By Key Countries/Region
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
3. New Product Launches, By Key Players
4. Pipeline Analysis, By Key Players
5. Regulatory & Reimbursement Scenario, By Key Countries/Region
Global Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ARNI
  3. Beta Blockers
  4. ACE Inhibitors & ARBs
  5. Mineralocorticoid Receptor Antagonists
  6. Diuretics
  7. Others
2. Market Analysis, Insights and Forecast – By Indication
  1. HFrEF
  2. HFpEF
  3. HFmrEF
  4. Acute Decompensated Heart Failure
  5. Post-MI Heart Failure / LV Dysfunction
  6. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
  4. Others
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Novartis AG
  2. AstraZeneca
  3. Boehringer Ingelheim International GmbH
  4. Merck & Co., Inc.
  5. Amgen Inc.
  6. Pfizer Inc.
  7. LEXICON PHARMACEUTICALS, INC.
  8. Viatris Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. Sandoz Inc.

Read Less

List of Figures

Figure 1: Global Heart Failure Drugs Market Revenue Breakdown (USD Billion, %) By Region, 2025 & 2034

Figure 2: Global Heart Failure Drugs Market Value Share (%), By Drug Class, 2025 & 2034

Figure 3: Global Heart Failure Drugs Market Value Share (%), By Indication, 2025 & 2034

Figure 4: Global Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 5: Global Heart Failure Drugs Market Value Share (%), By Type, 2025 & 2034

Figure 6: Global Heart Failure Drugs Market Value Share (%), By Age Group, 2025 & 2034

Figure 7: Global Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 8: Global Heart Failure Drugs Market Value Share (%), By Region, 2025 & 2034

Figure 9: North America Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 10: North America Heart Failure Drugs Market Value Share (%), By Drug Class, 2025

Figure 11: North America Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034

Figure 12: North America Heart Failure Drugs Market Value Share (%), By Indication, 2025

Figure 13: North America Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 14: North America Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025

Figure 15: North America Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034

Figure 16: North America Heart Failure Drugs Market Value Share (%), By Type, 2025

Figure 17: North America Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 18: North America Heart Failure Drugs Market Value Share (%), By Age Group, 2025

Figure 19: North America Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 20: North America Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 21: North America Heart Failure Drugs Market Value (USD Billion), by Country, 2025 & 2034

Figure 22: North America Heart Failure Drugs Market Value Share (%), by Country, 2025

Figure 23: Europe Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 24: Europe Heart Failure Drugs Market Value Share (%), By Drug Class, 2025

Figure 25: Europe Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034

Figure 26: Europe Heart Failure Drugs Market Value Share (%), By Indication, 2025

Figure 27: Europe Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 28: Europe Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025

Figure 29: Europe Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034

Figure 30: Europe Heart Failure Drugs Market Value Share (%), By Type, 2025

Figure 31: Europe Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 32: Europe Heart Failure Drugs Market Value Share (%), By Age Group, 2025

Figure 33: Europe Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 34: Europe Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 35: Europe Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 36: Europe Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 37: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 38: Asia Pacific Heart Failure Drugs Market Value Share (%), By Drug Class, 2025

Figure 39: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034

Figure 40: Asia Pacific Heart Failure Drugs Market Value Share (%), By Indication, 2025

Figure 41: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 42: Asia Pacific Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025

Figure 43: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034

Figure 44: Asia Pacific Heart Failure Drugs Market Value Share (%), By Type, 2025

Figure 45: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 46: Asia Pacific Heart Failure Drugs Market Value Share (%), By Age Group, 2025

Figure 47: Asia Pacific Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 48: Asia Pacific Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 49: Asia Pacific Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 50: Asia Pacific Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 51: Latin America Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 52: Latin America Heart Failure Drugs Market Value Share (%), By Drug Class, 2025

Figure 53: Latin America Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034

Figure 54: Latin America Heart Failure Drugs Market Value Share (%), By Indication, 2025

Figure 55: Latin America Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 56: Latin America Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025

Figure 57: Latin America Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034

Figure 58: Latin America Heart Failure Drugs Market Value Share (%), By Type, 2025

Figure 59: Latin America Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 60: Latin America Heart Failure Drugs Market Value Share (%), By Age Group, 2025

Figure 61: Latin America Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 62: Latin America Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 63: Latin America Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 64: Latin America Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 65: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 66: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Drug Class, 2025

Figure 67: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Indication, 2025 & 2034

Figure 68: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Indication, 2025

Figure 69: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 70: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Route of Administration, 2025

Figure 71: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Type, 2025 & 2034

Figure 72: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Type, 2025

Figure 73: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 74: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Age Group, 2025

Figure 75: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 76: Middle East & Africa Heart Failure Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 77: Middle East & Africa Heart Failure Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 78: Middle East & Africa Heart Failure Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 79: Global Heart Failure Drugs Market Share (%), by Company, 2025

List of Tables

Table 1: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 2: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 3: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 4: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 5: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 6: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 7: Global Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Region, 2021-2034

Table 8: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 9: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 10: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 11: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 12: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 13: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 14: North America Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country, 2021-2034

Table 15: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 16: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 17: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 18: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 19: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 20: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 21: Europe Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 22: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 23: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 24: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 25: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 26: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 27: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 28: Asia Pacific Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 29: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 30: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 31: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 32: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 33: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 34: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 35: Latin America Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 36: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 37: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Indication, 2021-2034

Table 38: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 39: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Type, 2021-2034

Table 40: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 41: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 42: Middle East & Africa Heart Failure Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 204

Buy Now

Download Free Sample

Security Code

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com